Plasminogen deficiency suppresses clinical symptoms of MAS in CpG/DG-injected mice. (A) Survival rate of CpG/DG-injected Plg^+/+ or Plg^−/− mice (n = 12 per group). (B) Percentage of WBC, RBC, and PLT set as 100% for day 0 in CpG/DG-injected Plg^+/+ or Plg^−/− mice at day 10 (n = 6-8 per group). (C) Mononuclear spleen cell counts of CpG/DG-injected Plg^+/+ or Plg^−/− mice at day 0 and day 10 (n = 5-7 per group). (D) Representative images of H&E-stained sections of liver isolated from CpG/DG-injected Plg^+/+ or Plg^−/− mice at days 0, 4, and 10. Scale bars = 200 μm. Black dotted lines indicate mononuclear cell infiltration; black arrows, hepatocellular degeneration. Right panel, Histopathological liver score in groups of these mice (n = 5 per group). (E) Representative H&E-stained BM section images of CpG/DG-injected Plg^+/+ or Plg^−/− mice at day 0 and day 10. Scale bars = 200 μm. Data represent mean ± SEM. *P < .05, **P < .01, ***P < .001, using 1-way ANOVA with the Tukey posttest or the unpaired, 2-tailed Student t test for significance and using the log-rank test for survival curves. N.S., not significant.